Jefferies analyst Roger Song raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $13.00 (from $11.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE